Low-Dose Aspirin Is the Safest Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty Across All Patient Risk Profiles.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: Disclosure: This project was supported by the Clinical and Translational Science Collaborative (CTSC) of Cleveland, which is funded by the National Institutes of Health (NIH), National Center for Advancing Translational Science (NCATS), Clinical and Translational Science Award (CTSA) grant UL1TR002548. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article ( http://links.lww.com/JBJS/I16 ). 6. Bone Joint J. 2020 Dec;102-B(12):1743-1751. doi: 10.1302/0301-620X.102B12.BJJ-2019-1136.R3. Venous thromboembolism in orthopaedic oncology. Lex JR(1)(2), Evans S(2), Cool P(3)(4), Gregory J(2), Ashford RU(5)(6), Rankin KS(7)(8), Cosker T(9), Kumar A(10), Gerrand C(11), Stevenson J(2)(12); British Orthopaedic Oncology Society VTE Committee. Author information: (1)Division of Orthopaedic Surgery, University of Toronto, Toronto, Canada. (2)Oncology Department, Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, UK. (3)Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK. (4)Medical School, Keele University, Keele, UK. (5)Joint Reconstruction and Oncology, University Hospitals of Leicester NHS Trust, Leicester, UK. (6)Leicester Cancer Research Centre, University of Leicester, Leicester, UK. (7)Translational and Clinical Sciences Institute, Newcastle University, Newcastle, UK. (8)North of England Bone and Soft Tissue Tumour Service, Newcastle upon Tyne University Hospitals NHS Foundation Trust, Newcastle, UK. (9)Orthopaedic Oncology, University of Oxford Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Oxford, UK. (10)Orthopaedics Department, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. (11)Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK. (12)Medical School, Aston University, Birmingham, UK. AIMS: Malignancy and surgery are risk factors for venous thromboembolism (VTE). We undertook a systematic review of the literature concerning the prophylactic management of VTE in orthopaedic oncology patients. METHODS: MEDLINE (PubMed), EMBASE (Ovid), Cochrane, and CINAHL databases were searched focusing on VTE, deep vein thrombosis (DVT), pulmonary embolism (PE), bleeding, or wound complication rates. RESULTS: In all, 17 studies published from 1998 to 2018 met the inclusion criteria for the systematic review. The mean incidence of all VTE events in orthopaedic oncology patients was 10.7% (1.1% to 27.7%). The rate of PE was 2.4% (0.1% to 10.6%) while the rate of lethal PE was 0.6% (0.0% to 4.3%). The overall rate of DVT was 8.8% (1.1% to 22.3%) and the rate of symptomatic DVT was 2.9% (0.0% to 6.2%). From the studies that screened all patients prior to hospital discharge, the rate of asymptomatic DVT was 10.9% (2.0% to 20.2%). The most common risk factors identified for VTE were endoprosthetic replacements, hip and pelvic resections, presence of metastases, surgical procedures taking longer than three hours, and patients having chemotherapy. Mean incidence of VTE with and without chemical prophylaxis was 7.9% (1.1% to 21.8%) and 8.7% (2.0% to 23.4%; p = 0.11), respectively. No difference in the incidence of bleeding or wound complications between prophylaxis groups was reported. CONCLUSION: Current evidence is limited to guide clinicians. It is our consensus opinion, based upon logic and deduction, that all patients be considered for both mechanical and chemical VTE prophylaxis, particularly in high-risk patients (pelvic or hip resections, prosthetic reconstruction, malignant diagnosis, presence of metastases, or surgical procedures longer than three hours). Additionally, the surgeon must determine, in each patient, if the risk of haemorrhage outweighs the risk of VTE. No individual pharmacological agent has been identified as being superior in the prevention of VTE events. Cite this article: Bone Joint J 2020;102-B(12)1743:-1751. DOI: 10.1302/0301-620X.102B12.BJJ-2019-1136.R3